Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Deferred Tax Liability (2018)

Karyopharm Therapeutics' Non-Current Deferred Tax Liability history spans 1 years, with the latest figure at $15.5 million for Q4 2018.

  • For Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $15.5 million; the TTM value through Dec 2018 reached $15.5 million, changed N/A, while the annual FY2018 figure was $15.5 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $15.5 million in Q4 2018 per KPTI's latest filing.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $15.5 million in Q4 2018 to a low of $15.5 million in Q4 2018.